23andMe News and Activities
Presence
23andMe is a biotechnology company that provides genetic testing services for consumers interested in exploring their ancestry, inherited traits, and potential health predispositions. The service involves DNA analysis which helps individuals gain insights into their genetic health, ancestries, and traits, making it appealing to those curious about genetic data-driven personal health and ancestry exploration.
23andMe products and services overview:
- Health + Ancestry Service
- Ancestry + Traits Service
- DNA Relative Finder
- Personal Genetic Reports
Employees: 700
23andMe is a company listed under the stock ticker ME (US).
They are in:
- Biotechnology50%
- Healthcare50%
Acquisition, funding and merger involving 23andMe.
- Regeneron Pharmaceuticals has announced the acquisition of 23andMe (posted on May 20 2025).
- 23andMe has filed for bankruptcy protection 23andMe (posted on March 25 2025).
Executives
View the org chart displaying its 23 main executives
Most searched biographies at 23andMe
Popular executive movements at 23andMe
- Anne Wojcicki, Chief Executive Officer and Director, has left the company (posted on March 25 2025).
- Mark Jensen has joined the company as Director (posted on October 30 2024).
- Jim Frankola has joined the company as Director (posted on October 30 2024).
Click here to view some more movements at 23andMe
Create your alert
to follow the executive moves at 23andMe.
Biotechnology
23andMe has 2,353 competitors including Incyte (United States (USA)), Anthos Therapeutics (United States (USA)) and Valneva (France).
Popular M&A news in Biotechnology
- Renasant Bio has just announced a $54 Million fundraising (posted on July 15 2025).
- Illimis Therapeutics has just announced a $42 Million fundraising (posted on July 14 2025).
- Nuclidium has just announced a $99 Million fundraising (posted on July 14 2025).
Popular contacts in Biotechnology
News
Press releases by 23andMe
- TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets | 23andMe, Inc.
- 23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation | 23andMe, Inc.
- 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process | 23andMe, Inc.
- 23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC | 23andMe, Inc.
- Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale | 23andMe, Inc.
- 23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology | 23andMe, Inc.
- 23andMe Reports Third Quarter Fiscal Year 2025 Financial Results | 23andMe, Inc.
- 23andMe Special Committee Announces Exploration of Strategic Alternatives | 23andMe, Inc.
- 23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation | 23andMe, Inc.
- 23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future | 23andMe, Inc.
- View more press releases Close
Social media about 23andMe
- 23andMe on Wikipedia, Google News & Yahoo Finance
- 23andMe on LinkedIn, Twitter & YouTube
